Drug Profile
Research programme: glutathione-pegylated liposome therapeutics - BBB Therapeutics
Alternative Names: 2B3-XXX; Brain-targeted liposomal therapeutics - to-BBBLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator to-BBB technologies; VIB
- Developer BBB Therapeutics; VIB
- Class Antibodies; Glucocorticoids; Hydrolases; Pregnadienetriols
- Mechanism of Action Immunosuppressants; Steroid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Alzheimer's disease; Brain cancer; CNS disorders; Inflammation; Multiple sclerosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in Netherlands (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Multiple-sclerosis in Netherlands (Parenteral)
- 04 Nov 2017 No recent reports of development identified for research development in Alzheimer's-disease in Netherlands (Parenteral, Liposomal)